IINDABA EZINKULU ZE-CHUANGKUN BIOTECH KWIMAKEKETHI YAPHEZULU I-SHANGHAI CHUANGKUN I-BIOTECH TB/NTM IKHITHI YOKUFUMANA I-AIDI YENUCLEIC(LYOPHILIZED) YAMNIKELWE YI-INDONESIA FDA!

Kutshanje, iShanghai Chuangkun Biotechnology Co., Ltd. ifumene isatifikethi sobhaliso sesibini sase-Indonesia FDA se-TB/NTM Nucleic Acid kit (lyophilized), inyathelwe yi-(12+3) yohlobo lwe-HPV yokubona ikiti ye-PCR kwinyanga enye edlulileyo.eyabhengeza ukuba iimveliso zeChuangkun Biotech zigunyaziswe yi-Indonesia FDA, iphucula iimveliso eziziphuhlisileyo, kwaye ikwabonelela ngenkxaso eyomeleleyo yeChuangkun Biotech ukwandisa ngakumbi imarike yamazwe ngamazwe.

Ngokwengxelo yeGlobal TB yoMbutho wezeMpilo weHlabathi weNgxelo ka-2022 ye-TB, abantu abaqikelelwa kwi-10.6 lezigidi baya kuba ne-TB ngo-2021. Isantya esonyuka nge-4.5% sasingaphezu konyaka ka-2020. Ngeli xesha i-1.6 yezigidi zabantu babulawa sisifo sephepha kulo nyaka uphelileyo (kubandakanywa ne-6.7% babephakathi abantu abaphila ne-HIV).Ngokwendawo, uninzi lwezehlo ze-TB ngo-2021 zazikwimimandla ye-WHO ye-South-East Asia (45%), i-Afrika (23%) kunye ne-Western Pacific (18%), kunye nezabelo ezincinci kwi-Eastern Mediterranean (8.1%), eMelika. (2.9%) kunye neYurophu (2.2%).Ukuthathela ingqalelo ubhubhani we-COVID-19, uthintelo kunye nolawulo lwesifo sephepha kuba nzima ngakumbi kwiSicwangciso sokuPheliswa kweSifo sePhepha se-WHO.

I-TB/NTM Nucleic Acid yokufumanisa ikiti esuka kwi-CHUANGKUN Biotech iyilwe yinkqubo ye-lyophilization .Le nkqubo iya kusombulula iingxaki zothutho zexesha elide kwikhithi yokukhangela ye-PCR yendabuko, kwaye izisa ukuchaneka okugqwesileyo kunye neziphumo ezicacileyo eziphezulu ngaphezu kokulula kokusetyenziswa kwethu.

I-Shanghai Chuangkun Biotechnology Co., Ltd. ifumene isatifikethi sobhaliso sesibini sase-Indonesia FDA se-TB/NTM Nucleic Acid yokufumanisa ikiti, ebonisa ukuvunywa yi-Indonesia FDA.I-Chuangkun Biotech iya kuzinikela ekuthatheni inxaxheba ekuthinteleni isifo sephepha kunye nokulawula ngokusebenzayo.